MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma DOI Creative Commons

Hongyu Xu,

Zedong Du, Zhihui Li

и другие.

Annals of Medicine, Год журнала: 2024, Номер 56(1)

Опубликована: Фев. 7, 2024

Background The chemotherapy resistance often leads to failure. This study aims explore the molecular mechanism by which MUC1 regulates paclitaxel in lung adenocarcinoma (LUAD), providing scientific basis for future target selection.

Язык: Английский

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer DOI
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills

и другие.

Nature reviews. Cancer, Год журнала: 2022, Номер 22(6), С. 323 - 339

Опубликована: Март 9, 2022

Язык: Английский

Процитировано

231

Mechanism of interaction between autophagy and apoptosis in cancer DOI
Shreya Das, Nidhi Shukla, Shashi Shekhar Singh

и другие.

APOPTOSIS, Год журнала: 2021, Номер 26(9-10), С. 512 - 533

Опубликована: Сен. 12, 2021

Язык: Английский

Процитировано

179

Unveiling the mechanisms and challenges of cancer drug resistance DOI Creative Commons
Sameer Ullah Khan, Kaneez Fatima,

Shariqa Aisha

и другие.

Cell Communication and Signaling, Год журнала: 2024, Номер 22(1)

Опубликована: Фев. 12, 2024

Abstract Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer strategies are evolving due to innate acquired capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells survive progress under unfavorable conditions. Although the mechanism of drug being widely studied generate new target-based drugs with better potency than existing ones. However, broader flexibility in resistance, advanced therapeutic options efficacy need be explored. Combination therapy an alternative a success rate though risk amplified side effects commonplace. Moreover, recent groundbreaking precision immune ways overcome has revolutionized anticancer greater extent only limitation individual-specific needs further attention. This review will focus on challenges opted withstand current therapies at molecular level also highlights emerging -like immunological, stem cell-based may prove have potential challenge problem resistance.

Язык: Английский

Процитировано

107

Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer DOI Open Access
Briana Kinnel, Santosh Kumar Singh,

Gabriela Oprea‐Ilies

и другие.

Cancers, Год журнала: 2023, Номер 15(4), С. 1320 - 1320

Опубликована: Фев. 19, 2023

Breast cancer is the most common cause of cancer-related death in women worldwide. Multidrug resistance (MDR) has been a large hurdle reducing BC rates. The drug mechanisms include increased efflux, enhanced DNA repair, senescence escape, epigenetic alterations, tumor heterogeneity, microenvironment (TME), and epithelial-to-mesenchymal transition (EMT), which make it challenging to overcome. This review aims explain further, identify viable targets, elucidate how those targets relate progression resistance.

Язык: Английский

Процитировано

84

Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success DOI Creative Commons
Sumel Ashique, Mithun Bhowmick, Radheshyam Pal

и другие.

Advances in Cancer Biology - Metastasis, Год журнала: 2024, Номер 10, С. 100114 - 100114

Опубликована: Янв. 17, 2024

A significant obstacle to treating cancer is multidrug resistance (MDR), which the capacity of cancerous cells develop both traditional and cutting-edge chemotherapeutic treatments. Following initial discovery that cellular pumps reliant on ATP were root chemotherapy resistance, more research has revealed involvement additional mechanisms, including increased drug metabolism, reduced entry, compromised apoptotic pathways. Numerous projects have focused MDR, innumerable been conducted better understand MDR methods mitigate its consequences. Multidrug (MDR) a key challenge in cancer. 90% cancer-related fatalities are brought by tumor metastasis recurrence, possible with MDR. Drug influenced diverse internal extrinsic variables, genetic epigenetic changes, efflux systems, DNA repair apoptosis, autophagy. In this review paper, we list potential hazards associated therapy general, primarily developing theory for colorectal particular. We discussed unique instance malignancies generally 5-fluorouracil, curcumin, lipids as viable options condition. The use nanotechnology (mainly nanoparticles) facilitated vitro well vivo efficacy during preclinical phases, summarized below, allowing thorough investigation cancers pancreatic carcinomas their translation following clinical trials.

Язык: Английский

Процитировано

52

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance DOI Open Access

Nauf Bou Antoun,

Athina‐Myrto Chioni

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(15), С. 12222 - 12222

Опубликована: Июль 30, 2023

One of the leading causes death worldwide, in both men and women, is cancer. Despite significant development therapeutic strategies, inevitable emergence drug resistance limits success impedes curative outcome. Intrinsic acquired are common mechanisms responsible for cancer relapse. Several factors crucially regulate tumourigenesis resistance, including physical barriers, tumour microenvironment (TME), heterogeneity, genetic epigenetic alterations, immune system, burden, growth kinetics undruggable targets. Moreover, transforming factor-beta (TGF-β), Notch, epidermal factor receptor (EGFR), integrin-extracellular matrix (ECM), nuclear kappa-light-chain-enhancer activated B cells (NF-κB), phosphoinositol-3-kinase/protein kinase B/mammalian target rapamycin (PI3K/Akt/mTOR), wingless-related integration site (Wnt/β-catenin), Janus kinase/signal transducers activators transcription (JAK/STAT) RAS/RAF/mitogen-activated protein (MAPK) signalling pathways some key players that have a pivotal role mechanisms. To guide future treatments improve results, deeper comprehension necessary. This review covers intrinsic gives comprehensive overview recent research on enable to bypass barriers put up by treatments, and, like “satellite navigation”, find alternative routes which carry their “journey” progression.

Язык: Английский

Процитировано

48

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities DOI Creative Commons
Michael S. Yu, Kevin Qin, Jiaming Fan

и другие.

Genes & Diseases, Год журнала: 2023, Номер 11(3), С. 101026 - 101026

Опубликована: Июль 22, 2023

The evolutionarily conserved Wnt signaling pathway plays a central role in development and adult tissue homeostasis across species. proteins are secreted, lipid-modified molecules that activate the canonical (β-catenin dependent) non-canonical independent) pathways. Cellular behaviors such as proliferation, differentiation, maturation, proper body-axis specification carried out by pathway, which is best characterized of known paths. has emerged an important factor stem cell biology to affect self-renewal cells various tissues. This includes but not limited embryonic, hematopoietic, mesenchymal, gut, neural, epidermal cells. also been implicated tumor exhibit cell-like properties. crucial for bone formation presents potential target therapeutics disorders. Not surprisingly, aberrant associated with wide variety diseases, including cancer. Mutations members cancer can lead unchecked epithelial-mesenchymal transition, metastasis. Altogether, advances understanding dysregulated disease have paved way novel components pathway. Beginning brief overview mechanisms Wnt, this review aims summarize current knowledge cells, aberrations targeting preclinical clinical studies.

Язык: Английский

Процитировано

45

DNA Repair and Therapeutic Strategies in Cancer Stem Cells DOI Open Access

Matthew S. Gillespie,

Ciara Ward,

Clare C. Davies

и другие.

Cancers, Год журнала: 2023, Номер 15(6), С. 1897 - 1897

Опубликована: Март 22, 2023

First-line cancer treatments successfully eradicate the differentiated tumour mass but are comparatively ineffective against stem cells (CSCs), a self-renewing subpopulation thought to be responsible for initiation, metastasis, heterogeneity, and recurrence. CSCs thus presented as principal target elimination during treatment. However, challenging drug because of numerous intrinsic extrinsic mechanisms resistance. One such mechanism that remains relatively understudied is DNA damage response (DDR). presumed possess properties enable enhanced repair efficiency relative their highly proliferative bulk progeny, facilitating improved double-strand breaks induced by radiotherapy most chemotherapeutics. This can occur through multiple mechanisms, including increased expression splicing fidelity genes, robust activation cell cycle checkpoints, elevated homologous recombination-mediated repair. Herein, we summarise current knowledge concerning genome integrity in non-transformed CSCs, discuss therapeutic opportunities within DDR re-sensitising genotoxic stressors, consider challenges posed regarding unbiased identification novel DDR-directed strategies CSCs. A better understanding mediating chemo/radioresistance could lead approaches, thereby enhancing treatment efficacy patients.

Язык: Английский

Процитировано

44

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future DOI Creative Commons
Wei Wang,

Najah Albadari,

Yi Du

и другие.

Pharmacological Reviews, Год журнала: 2024, Номер 76(3), С. 414 - 453

Опубликована: Март 15, 2024

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM29s activities extend from carcinogenesis to immunity, response various therapies. report first inhibitor more than 30 approaches inhibit have been attempted, with hundreds small molecule inhibitors evaluated in preclinical studies and numerous molecules tested clinical trials. Although many degraders trials, there is currently no FDA-approved on market. Nevertheless, are several current trials promising agents that may overcome past failures, including granted FDA orphan drug or fast-track status. We herein summarize research efforts discover develop inhibitors, focusing those induce degradation exert anticancer activity, regardless p53 status cancer. also describe how investigations moved towards combining other agents, immune checkpoint inhibitors. Finally, we discuss challenges future directions accelerate application In conclusion, targeting remains a treatment approach, protein represents novel strategy downregulate without side effects existing blocking p53-MDM2 binding. Additional needed finally realize full potential inhibition treating chronic diseases where implicated. Significance Statement Overexpression/amplification oncogene detected human cancers associated disease progression, resistance, poor patient outcomes. Herein, review previous, emerging MDM2-targeted therapies chemotherapy immunotherapy regimens. The findings these contemporary lead safer effective treatments patients overexpressing MDM2.

Язык: Английский

Процитировано

39

Hallmarks of cancer resistance DOI Creative Commons
Muhammad Tufail,

Jia-Ju Hu,

Jie Liang

и другие.

iScience, Год журнала: 2024, Номер 27(6), С. 109979 - 109979

Опубликована: Май 15, 2024

This review explores the hallmarks of cancer resistance, including drug efflux mediated by ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized Warburg effect, and dynamic interplay between cells mitochondria. The role stem (CSCs) in treatment resistance regulatory influence non-coding RNAs, such as long RNAs (lncRNAs), microRNAs (miRNAs), circular (circRNAs), are studied. chapter emphasizes future directions, encompassing advancements immunotherapy, strategies to counter adaptive integration artificial intelligence for predictive modeling, identification biomarkers personalized treatment. comprehensive exploration these provides a foundation innovative therapeutic approaches, aiming navigate complex landscape enhance patient outcomes.

Язык: Английский

Процитировано

25